Approach to frontline therapy in elderly chronic lymphocytic leukemia patients

Ohad Benjamini, Alessandra Ferrajoli, Michael J. Keating*

*Corresponding author for this work

Research output: Contribution to journalReview articlepeer-review


Although the majority of chronic lymphocytic leukemia patients are diagnosed at an older age, most of our knowledge is based on data from clinical trials of young patients. Hence, not all the prognostic factors are valid in the elderly and no standard treatment has been established. Elderly patients are heterogeneous in their competency to tolerate treatment and most require treatment modifications. Recent studies are focusing on the incorporation of dose-attenuated regimens, less myelotoxic drugs and new therapies. Monoclonal antibodies, immunomodulatory drugs and small molecules, such as B-cell receptor pathway inhibitors, may dramatically change the treatment options for and outcome of elderly chronic lymphocytic leukemia patients.

Original languageEnglish
Pages (from-to)331-347
Number of pages17
JournalAging Health
Issue number3
StatePublished - Jun 2013
Externally publishedYes


  • chronic lymphocytic leukemia
  • clinical trial
  • comorbidity
  • elderly
  • frail
  • old
  • prognosis
  • slow go
  • treatment


Dive into the research topics of 'Approach to frontline therapy in elderly chronic lymphocytic leukemia patients'. Together they form a unique fingerprint.

Cite this